Shiba Inu (SHIB) exchange reserves decreased by 33.94 billion tokens over 24 hours, bringing the total to 87.06 trillion tokens. This net outflow means more tokens were withdrawn than deposited, but it does not confirm increased buying demand or accumulation by holders. Analysts note that a further drop below 86 trillion tokens could indicate reduced exchange holdings, but price impact depends on actual demand, which current data does not clarify.
Shiba Inu (SHIB) exchange reserves recently stood at 87.06 trillion tokens, showing a net outflow of 33.94 billion tokens over 24 hours. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 21, 2026 05:11 WIB: out of 50 major cryptocurrencies priced on Pluang, 44 rose and 5 fell today. Notable movers include COMP (Compound) at Rp475.589 with a 1-day change of +23.17% and Pluang order activity of 32% Sell / 68% Buy, THETA (Theta Network) at Rp3.746 with +11.62% change and 100% Sell order activity, and BAL (Balancer) at Rp16.297 with +11.14% change.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
